Comparative Analysis of the Pipeline and the Derivo Flow Diverters for the Treatment of Unruptured Intracranial Aneurysms—A Multicentric Study

Zaeske, Charlotte; Goertz, Lukas; Dorn, Franziska; Turowski, Bernd; Abdullayev, Nuran; Schlamann, Marc; Liebig, Thomas; Kabbasch, Christoph

doi:10.1016/j.wneu.2020.10.062

Cited by 8 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another positive point of our study is the heterogeneity of the treated aneurysms. Our results are therefore likely to be representative of real-life data, similar to what has been described in the literature 2 6–11. We conducted a query for “Derivo” in the PubMed online database (last search on June 7, 2021), which yielded 21 articles.…”

Section: Discussionsupporting

confidence: 74%

“…The efficacy of total occlusion (OKM D) was 70.1% (122/174) at 6 months and 83.3% (145/174) at 1 year. However, if we consider total occlusion (OKM D) and also favorable aneurysm occlusion (OKM C+D), as is the case in most published reports,2 7–11 the occlusion rate in our sample was 87.3% (152/174) at 6 months and 97.7% (170/174) at 12 months.…”

Section: Discussionmentioning

confidence: 55%

“…With the advent of flow diverters and the rapid development of new devices, a number of studies have been conducted in recent years to assess their effectiveness and safety 2–4. However, despite technical improvements, only a few large studies have attempted to assess the long-term efficacy and safety of the DED 2 6–11…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Endovascular treatment of intracranial aneurysms using the Derivo Embolization Device: a multicenter experience

Lourenço

Dantas

Carvalho

et al. 2022

J NeuroIntervent Surg

View full text Add to dashboard Cite

BackgroundFlow diversion is the first-line treatment for several types of intracranial aneurysms. We report on a large series of patients treated with the Derivo Embolization Device who underwent a 1-year angiographic control follow-up.MethodsWe performed a multicenter retrospective analysis of prospectively collected data, designed to evaluate the clinical and angiographic results of treatment of intracranial aneurysms with the Derivo Flow Diverter. The primary endpoint was complete occlusion of the aneurysm within 12 months, which was evaluated using DSA. The secondary endpoint was the absence of any serious adverse events. Univariate and multivariate logistic regression analyses were performed to analyze the data.ResultsThe study was conducted from December 2016 to September 2019 and enrolled 127 patients with 177 intracranial aneurysms, treated at three different centers. Efficacy at 6 months was 70.1% (122/174) for total occlusion and 87.3% (152/174) for favorable occlusion and, at 12 months, it was 83.3% (145/174) for total occlusion and 97.7% (170/174) for favorable occlusion. Regarding safety concerns, 97.6% (124/127) of patients did not experience severe adverse effects during the follow-up period of 12 months, and there was no procedure-related mortality.ConclusionsThe Derivo Embolization Device, achieving a total occlusion rate of 83.3% and a favorable occlusion rate of 97.7% in a 1-year angiographic control study of 174 aneurysms with minor morbidity and no intervention-related mortality, is a safe and effective treatment for intracranial aneurysms.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Endovascular treatment of intracranial aneurysms using the Derivo Embolization Device: a multicenter experience

Lourenço

Dantas

Carvalho

et al. 2022

J NeuroIntervent Surg

View full text Add to dashboard Cite

show abstract

“…The comprehensive adverse event rate was comparable between both groups (PED: 5.4%, DED: 8.2%, P 1∕4 0.713) according to the article [56]. Both the PED group and DED group have 3 cases that have occurred thromboembolic phenomenon, which was 4.1% risk of occurrence in the 62 patients PED group and 6.1% in the 39 patients DED group.…”

Section: Procedural Adverse Events (Hemorrhagic and Thromboembolic Events)mentioning

confidence: 70%

A comprehensive review of intracranial aneurysm and comparison between different treatment to the disease

Zhang¹

2021

E3S Web Conf.

View full text Add to dashboard Cite

An intracranial aneurysm is an abnormal protrude in the intracranial arteries’ wall, which is the primary cause of hemorrhagic arachnoid. It is the third cerebrovascular disease besides cerebral thrombosis and hypertensive cerebral hemorrhage. There are many methods of treating intracranial aneurysms. Different methods have different outcomes and have their own advantages and drawbacks. This review provides comprehensive information on intracranial aneurysms and focuses on the comparison of different clinical methods treating this disease. Given the significant health concern of intracranial aneurysms, more attention should be paid, and innovative treating methods would be reasonably expected.

show abstract

“…These complications, such as strokes caused by device occlusions, ISS, or occlusions of covered branches, as well as delayed aneurysm ruptures, can have serious consequences for the patient and are the subject of ongoing research. 19–23…”

Section: Discussionmentioning

confidence: 99%

Endovascular treatment of unruptured intracranial aneurysms with flow diverters: A retrospective long-term single center analysis

et al. 2022

View full text Add to dashboard Cite

Purpose The introduction of flow diverters (FDs) in 2007 greatly enhanced the treatment of intracranial aneurysms. Here, we present our long-term clinical experience in treating unruptured intracranial aneurysms with FDs. Methods 107 patients with unruptured aneurysms and treated with an FD between 2010 and 2019 were retrospectively reviewed. Aneurysm occlusion, procedural complications, and clinical outcome were evaluated. Results Angiographic follow-up was available for 93 patients with a mean long-term follow-up time of 28.4 ± 21.6 months. Additional coiling was performed in 15.1% of patients ( n = 14). Adequate aneurysm occlusion (Kamran grades 3 and 4) at long-term follow-up was achieved in 94.6% of patients ( n = 88). 3.2% ( n = 3) required endovascular retreatment since the last follow-up showed a lack of aneurysm occlusion (Kamran grade 0) due to a foreshortening of the FD. Incomplete opening of the FD and parent vessel occlusion was seen in 1.1% ( n = 1) and 3.2% ( n = 3) of patients, respectively. In-stent stenosis was observed in 57% ( n = 53) of cases at short-term follow-up and 22.6% ( n = 21) at long-term, which were moderate and asymptomatic overall. In-stent stenosis decreased significantly between short- and long-term follow-ups (31.4 ± 17.0% vs 9.7 ± 13.6%, respectively; p ≤ 0.001). Thromboembolic and hemorrhagic events occurred in 7.5% ( n = 7) and 1.1% ( n = 1) of patients, respectively. Good clinical outcome (modified Rankin scale: 0–2) was obtained in 97.8% ( n = 91) leading to an overall treatment-related morbidity of 2.2% ( n = 2). There was no procedural mortality. Conclusion Our study shows that FD treatment of unruptured intracranial aneurysms is effective and safe with high occlusion rates and low rates of permanent morbidity at long-term follow-up.

show abstract

Comparative Analysis of the Pipeline and the Derivo Flow Diverters for the Treatment of Unruptured Intracranial Aneurysms—A Multicentric Study

Cited by 8 publications

References 23 publications

Endovascular treatment of intracranial aneurysms using the Derivo Embolization Device: a multicenter experience

Endovascular treatment of intracranial aneurysms using the Derivo Embolization Device: a multicenter experience

A comprehensive review of intracranial aneurysm and comparison between different treatment to the disease

Endovascular treatment of unruptured intracranial aneurysms with flow diverters: A retrospective long-term single center analysis

Contact Info

Product

Resources

About